Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol. 2014 Jul 28;12: 234.Zhang JJ, Sun WJ, Huang ZX, et al.: Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. ...
Multiple Myeloma Robert A.KyleMD, ...S. VincentRajkumarMD, inHematology/Oncology Clinics of North America, 2014 Light Chain MGUS Light chainMGUSis defined as the presence of an abnormal FLC ratio (normal 0.26–1.65), nomonoclonal immunoglobulinheavy chain, an increased concentration of the involve...
Cutaneous light chain amyloidosis with multiple myeloma: A concise review. Cutaneous immunoglobulin (Ig) amyloid light-chain (AL) amyloidosis associated with overt multiple myeloma (MM) is rare and optimal treatment is not well de... Mirela,Andrei,Jen,... - 《Hematology/oncology & Stem Cell The...
Light chain amyloidosis needs to be considered in the differential diagnosis of patients with nondiabetic nephrotic range proteinuria, unexplained fatigue or heart failure with preserved ejection fraction, a progressive peripheral neuropathy associated with a monoclonal protein, or atypical multiple myeloma. ...
NCCN Guidelines Version 2.2023 Systemic Light Chain Amyloidosis Overview Primary systemic light chain amyloidosis (SLCA) in contrast to multiple myeloma is typically characterized by low burden of monoclonal plasma cells in the bone marrow. The abnormal plasma cells produce light chains that get ...
Eight amyloidogenic LCs were selected as responsible for severe cardiac symptoms in patients; five non-amyloidogenic LCs were isolated from patients affected by multiple myeloma. Our comprehensive approach (consisting of spectroscopic techniques, limited proteolysis, and X-ray crystallography) shows that ...
patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on...
Herein, we describe the case of a 53-year-old female diagnosed with systemic mastocytosis (SM) in conjunction with renal light chain amyloidosis (AL) and smoldering myeloma. Although cytokines such as IL-6 may play a role in the proliferation of plasma cells, delays in the diagnosis of SM...
Kappa light chain multiple myeloma was diagnosed by bone marrow aspiration, biopsy and immunoelectrophoresis of serum and urine. He was treated with mephalan, prednisolone and diuretics. 展开 年份: 1994 收藏 引用 批量引用 报错 分享 全部来源 求助全文 papersearch.net 相似文献...
CD38 is a surface protein that is present in high numbers on multiple myeloma cells, regardless of the stage of disease. Daratumumab binds to CD38 and inhibits tumour cell growth causing myeloma cell death. Darzalex Faspromay also have an effect on normal cells. ...